Table 2 Rate of decline in FEV1, FVC, and FEV1/FVC ratio
From: The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
Tiotropium Respimat® 5 μg (n = 461) | Tiotropium Respimat® 2.5 μg (n = 464) | Tiotropium HandiHaler® 18 μg (n = 445) | |
|---|---|---|---|
Rate of decline in FEV1 | |||
Annual rate of decline, mL | 26 | 40 | 34 |
Difference to HandiHaler® 18 μg, mL (95 % CI) | −8 (−26,10); p = 0.3771 | 5 (−12, 23); p = 0.5537 | |
Difference to Respimat® 5 μg, mL (95 % CI) | 13 (−4, 31); p = 0.1350 | ||
Rate of decline in FVC | |||
Annual rate of decline, mL | 35 | 50 | 52 |
Difference to HandiHaler® 18 μg, mL (95 % CI) | −17 (−48, 13); p = 0.2627 | −3 (−33, 28); p = 0.8549 | |
Difference to Respimat® 5 μg, mL (95 % CI) | 15 (−15, 44); p = 0.3423 | ||
Rate of decline in FEV1/FVC | |||
Annual rate of decline, % | 0.29 | 0.57 | 0.24 |
Difference to HandiHaler® 18 μg, % (95 % CI) | 0.04 (−0.42, 0.50); p = 0.8543 | 0.33 (−0.13, 0.78); p = 0.1627 | |
Difference to Respimat® 5 μg, % (95 % CI) | 0.28 (−0.17, 0.74); p = 0.2191 |